An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.29.15_SUPPL.7500PMID 28023291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Role of HSP90 in Cancer

  2021cites this paper
• Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics

  2021cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.

  2018cites this paper
• Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.

  2017cites this paper
• KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.

  2016cites this paper
• Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.

  2016cites this paper
• TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

  2016cites this paper
• Targeting the Protein Quality Control (PQC) Machinery

  2015cites this paper
• The treatment of advanced non-small-cell lung cancer with anaplastic lymphoma kinase genetic alterations: reality and hopes

  2015cites this paper
• Therapeutic management of ALK+ nonsmall cell lung cancer patients

  2015cites this paper
• IDENTIFICATION OF NOVEL HEAT SHOCK RESPONSE MODULATORS FOR EXPERIMENTAL ANTI-MELANOMA INTERVENTION

  2015cites this paper
• Maximizing the Therapeutic Potential of HSP90 Inhibitors

  2015cites this paper
• ТЕРАПИЯ ALK-ПОЗИТИВНОГО НЕМЕЛКОКЛЕТОчНОГО РАКА ЛЕГКОГО: РЕАЛЬНОСТЬ И ПЕРСПЕКТИВЫ

  2014cites this paper
• A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

  2014cites this paper
• Therapy with ALK-positive non-small cell lung cancer: reality and prospects

  2014cites this paper
• Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.

  2014cites this paper
• Novel and Emerging Agents in NSCLC

  2014cites this paper
• Targeting Ectopic Hsp90 in Breast Cancer

  2014cites this paper
• Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

  2013cites this paper
• Second-Line Therapy for Advanced NSCLC.

  2013cites this paper
• NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

  2013cites this paper
• The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

  2013cites this paper
• Clinical use of crizotinib for the treatment of non-small cell lung cancer

  2013cites this paper
• Treatment and detection of ALK-rearranged NSCLC.

  2013cites this paper
• Crizotinib in the treatment of non-small-cell lung carcinoma

  2013cites this paper
• Including Intracranial Metastases against Multiple Models of Drug Resistance to Targeted Agents, NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity

  2013cites this paper
• Cancer Therapy : Preclinical NMS-E 973 , a Novel Synthetic Inhibitor of Hsp 90 with Activity against Multiple Models of Drug Resistance to Targeted Agents , Including Intracranial Metastases

  2013cites this paper
• Lung Cancer Growth Small Cell - The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non

  2013cites this paper
• Présélection de sujets pour un traitement thérapeutique comprenant un inhibiteur de hsp90 fondée sur l'état hypoxique

  2013cites this paper
• Crizotinib : une thérapeutique ciblant le réarrangement EML4-ALK chez les patients porteurs d’un cancer bronchique non à petites cellules métastatique

  2013cites this paper
• KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer

  2013cites this paper
• Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients

  2013cites this paper
• Impact of genetic markers on treatment of non-small cell lung cancer.

  2013cites this paper
• Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

  2013cites this paper
• Hsp90: still a viable target in prostate cancer.

  2013cites this paper
• KRAS mutation: should we test for it, and does it matter?

  2013cites this paper
• Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

  2013cites this paper
• Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

  2013cites this paper
• A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

  2013cites this paper
• Hsp90, an unlikely ally in the war on cancer

  2013cites this paper
• Inhibition of HSP90 molecular chaperones: moving into the clinic.

  2013cites this paper
• The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer

  2012cites this paper
• Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.

  2012cites this paper
• Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

  2012cites this paper
• Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements

  2012cites this paper
• HSP90 inhibitor antagonizing MIF

  2012cites this paper
• Treating ALK-positive lung cancer—early successes and future challenges

  2012cites this paper
• Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

  2012cites this paper
• Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

  2012cites this paper
• Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.

  2012cites this paper
• Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

  2012cites this paper
• HSP90 as a platform for the assembly of more effective cancer chemotherapy.

  2012cites this paper
• Recent Advances in Lung Cancer: Summary of Presentations from the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011

  2012cites this paper
• Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer

  2012cites this paper
• The Biology and Clinical Features of Non–small Cell Lung Cancers with EML4-ALK Translocation

  2012cites this paper
• Preclinical Development Targeting KRAS-Mutant Non – Small Cell Lung Cancer with the Hsp 90 Inhibitor Ganetespib

  2012cites this paper
• Polythérapie anticancéreuse d'inhibiteur de hsp90 comprenant un anti-métabolite

  2012cites this paper
• Translocation EML4-ALK : Techniques de détection, variantes, implications thérapeutiques

  2012cites this paper
• Acquired resistance to crizotinib is an urgent event that needs to be solved. Second-generation ALK inhibitors or combination therapy may be an effective strategy to overcome this problem.

  2012cites this paper
• Gene fusions in non-small-cell lung cancer

  2012cites this paper
• ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

  2012cites this paper
• Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

  2012cites this paper
• Recent updates on the development of ganetespib as a Hsp90 inhibitor

  2012cites this paper
• Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

  2011influential citation
• New Strategies for Treatment of ALK-Rearranged Non–Small Cell Lung Cancers

  2011cites this paper
• Cost Implications for Novel Therapies and Strategies in the Treatment of NSCLC: Perspectives and Clinical Updates from ASCO 2011

  2011cites this paper
• Personalized medicine in non-small- cell lung cancer: has it come of age?

  2011cites this paper
• [American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].

  2011cites this paper